Formulary Committee members with a potential conflict of interest permission to participate in committee communications and discussions

2025-2026 Regular Session Introduced by Liz Boldon

SF 4978 would allow Formulary Committee members with potential conflicts to participate in communications and discussions, under safeguards to manage COI.

Referred to Health and Human Services

#committees #healthandhealthdepartment

Purpose and Intent

The bill appears to address the participation of Formulary Committee members who may have a potential conflict of interest (COI) in committee communications and discussions.

Specifically, it provides a framework that permits these members to participate in communications and discussions despite a potential COI, presumably to ensure the committee can operate with input from stakeholders or members who might otherwise be restricted.

Key Provisions (as indicated by the bill’s title and summary)

Authorization for Formulary Committee members who have a potential COI to participate in committee communications and discussions.

The bill likely delineates the circumstances under which such participation is permitted, including any conditions or limitations designed to manage COI risk.

It may specify compliance requirements, transparency measures, and records related to such participation (e.g., disclosures, recusal when conflicts become material, or documentation of the decision to permit participation).

Who and What Would Be Affected

Formulary Committee Members: Those who have a potential COI related to formulary decisions and who seek to participate in communications and discussions.

Formulary Process/Decisions: The deliberations and communications surrounding formulary listings, coverage determinations, or related formulary management activities.

Stakeholders and Public Interest: Potentially including patients, providers, manufacturers, and payers who rely on the formulary process for decisions on covered medications.

Procedural and Timeline Aspects

Introduction and First Reading: 2026-04-07.

Referral: Referred to Health and Human Services on 2026-04-07.

Sponsor: Co-sponsor Liz Boldon (indicating advocacy or support within the committee or relevant policy domain).

Note: The bill’s full text would provide the precise procedural requirements (e.g., voting thresholds, disclosure standards, applicable conflicts-of-interest rules, and any limitations on participation). The summary above reflects the bill’s core aim inferred from its title and available action history.

Practical Considerations

The legislative change would likely aim to balance the need for broad expertise and input on formulary decisions with safeguards to manage conflicts of interest.

Potential questions for readers include:

What specific types of conflicts are addressed (financial, professional, fiduciary, etc.)?
Under what conditions can a COI member participate without compromising decision integrity?
What disclosure and recusal requirements accompany such participation?
How will transparency be maintained for public accountability?

Summary

SF 4978 seeks to permit Formulary Committee members who may have a potential conflict of interest to participate in committee communications and discussions, subject to conditions likely designed to manage COI risk. The bill has been introduced and referred to the Health and Human Services committee, with Liz Boldon listed as a co-sponsor. Further details from the bill’s full text would clarify the exact scope, safeguards, and implementation timeline.

Bill